Tarentum, PA, United States of America

Ralph E Schriver

This inventor holds 1 USPTO granted patent. Top assignee: Medrad, Inc.. Active years: 2012.


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 56(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Ralph E. Schriver

Introduction: Ralph E. Schriver is a notable inventor based in Tarentum, Pennsylvania. He has made significant contributions to the field of medical devices, particularly with his innovative designs in syringes. His work has had a lasting impact on the healthcare industry.

Latest Patents: Ralph E. Schriver holds a patent for a "Syringe having a proximal end with an outward extending lip." This invention features a body with a distal end, a proximal end, and a center section in between. It includes a plunger that is movably disposed in the body and a hollow alignment flange for orienting and manipulating the syringe. This design enhances the usability and effectiveness of syringes in medical applications.

Career Highlights: Schriver is currently employed at Medrad, Inc., a company known for its advancements in medical imaging and device technology. His role at Medrad has allowed him to further develop his innovative ideas and contribute to the company's mission of improving patient care.

Collaborations: Throughout his career, Ralph has worked alongside talented individuals such as Michael A. Spohn and Thomas P. Joyce. These collaborations have fostered a creative environment that has led to the development of groundbreaking medical technologies.

Conclusion: Ralph E. Schriver's contributions to the field of medical devices, particularly through his patented syringe design, exemplify his commitment to innovation. His work continues to influence the healthcare industry, making medical procedures safer and more efficient.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…